BMI body mass index; CT computed Tomography; ICU intensive care unit; BiPAP Bi-level Airway Positive Pressure; *censored means patients without outcome results

For secondary endpoints, AZM-Corticosteroid decreased the length of hospital stay in 1.5 day (𝛃 -1.5 95%CI -4.9 to 1.9), while HCQ use increased in 6.9 days (𝛃 6.9 95%CI 3.6 to 10.3). AZM-Corticosteroid and therapeutic anticoagulation combination reduced the ICU length stay in 1.5 day (𝛃 -1.5 95%CI -9.7 to 6.7) and MV in 4 days (𝛃 -4.0 95%CI -13.4 to 5.3), however, this effect was not observed when HCQ was associated (Figure 3). For the AZM-Corticosteroid and therapeutic anticoagulation the mean length of ICU stay was 15.9 days, but when HCQ was included, this time was increased to 40.3 days (Figure 3). There was a trend to more time in MV in obese patients. All models were adjusting for sex, age, obesity, pulmonary involvement, D-dimers, CRP, oxygen support without positive pressure (nasal catheter and Hudson mask) and length of hospital stay. Regarding HCQ have been used or not, the comparability of the groups was verified in relation to the clinical predictors for mortality, where there was no difference was observed among those who received the drug or not between those treated or not with HCQ.